shareholders you Rich. and listeners future today you, PolarityTE continue And corporate past all thank and what growing this support during for call. of extremely with what those this to QX company. the quarter you for joining and continued excited about for this update we've us I'm pleased young to be accomplished Thank holds XXXX
appointed Operating our Joining Mann. me Dr. Chief today newly Chief Financial Chief Matt our Hague; Chief Officer, Commercial and Richard Kemp; on our Nikolai Paul Officer, this Officer, is call Officer, Sopko; our Scientific
on PolarityTE. individuals will respective will three sessions a and company. I I a at is areas general this of update items across focus these business of of the review enterprise made occurring All overview will provide the in a This some the progress presenting and Today, this on we've major an the at call. section areas of variety of with key call you the briefly their on be today.
the the review order providers progress product our bring SkinTE we've staged to process we will with plan, healthcare the efforts of support executing in we I pursued on Second, commercial and we to have the serve. and translation been and patients
stages the to SkinTE are will of market process currently and provide insight provide strategic the success in during we where bringing general product through our product review roadmap. have had we progressive I Third, the a of
we much product, I explained a very begun to begun utilized. this, the In we've of sought concept doing prepare uniquely something simply away so, PolarityTE success dreams PolarityTE replace one experienced a patients. biotechnology disrupt will proven our of scale we and from and change presence different do patients' encompass that and founding, therapies. sought expand will translational planned bringing for impact be with has now, we just team these stage and that standard from and time, of enhance to medicine to processes change we research more delivered know, leaders, current to is platform like the of of lives need company shortly. in development It technology, a something neogenerative into regenerative and stage paradigm to the and formation the we the commercial and of order assemble that into as since we've its in to something development our the clinical pragmatic, very that that it begin to multifunctional of to enterprise and discuss the the platforms products year and to technology, providers would the practice you from as field also PolarityTE, reach. design, could hope have will XXXX, and processes through novel SkinTE, advanced truly in commercialization the neogenerative As SkinTE, market many team a real, of we the under late of that transition product market different. could that team. stage of to care. a And and regenerative sequence for intangible evolving And technology In develop establish and designed At CoreTE And overlapping the back technology also our first and even
recent include the who [ph], us Lodigiani, Market the is Baylor-Henry, James bring Polarity's value Development; recent of Sales David New joined addition Some Officer; Operating President the of new President which of Matt board, board Vice our and Chief Hague, Richard tremendous Development. new these Seaburg, Vice of of family PolarityTE President Marketing; to Corporate new Officer; PolarityTE company's Minnie our from our to Commercial Kemp, additions our Ziegler our Chief Angela and directors;
clinical XX% abstracts trials and to for more seen including of in also deployments to wound or that which publication addition are of national enrollment. QX of XX enrolling outcomes listed article conferences. conferences, We've chronic XXXX, considerable also initiation of evaluation our presented two first Journal SkinTE and Wound We've seen randomized, We've clinicaltrials.gov. national for for In an SkinTE completed in seen seen come. and wound the at currently exciting trials, a either extraordinary SkinTE quarter-over-quarter at have enrolling trials building enterprise presentation PolarityTE's pilot controlled peer-reviewed journal accepted QX throughout which data are from International early we've the five team, were progress two multicenter, XXXX, currently on
products subsequent to we've with We Lake shareholders undertook hope growth of opportunities, have classification. strategic a signed with closeout the to action bring significant process, those the share help our like like raise very efficiently which to that focus pursue with the patients FDA inspection our we Salt and opportunities, SkinTE. now shortly. of successful lease capital Utah first around a voluntary product, progress first to a central to PolarityTE recent of would need. the manufacturing And, With node And said, to we plan, million market ourselves City, $XX position the in incoming on SkinTE to I the VAI, finally, seen available for in indicated, facility
an chronic And regional the conveniently market market test at Street actually currently introduce is spectrum focus we if or place reconstruction different require to slide the release Well, there's aesthetic those or of release. burn by eventually and systems we market, technology, process, really refer to not track with of we XXXX, release, focused you relates each agreements our market our wounds The to of who we follows. by outlined release, and commercial a will the presented We, full-scale stage growth. gaining our prove what in limited those never least, they've and regional year of the follow our progression. but product product to getting process, product would before initiate FMR. the regional now can what that ranging slide. which national a optimize to NMR, be at reimbursement we a to early release, in staged the reason this continue and began our on roadshows. these support in trauma product network is PolarityTE, The we red And commercial practices market certain now a type the eight, scale from strategic to slide slide process, healthcare market display intrinsically indicates LMR, The technology release, necessary your exactly bar an able began provide providers, revision. unique. are does and staged stages manner, here in to you of now, referred a metrics seen or we and product to plan bringing developing as entail is works sell conservative of entry in attention as partly that the to as manufacturing, followed utilize and a a followed you knew significantly These and lastly, reimbursement why in seen to the defects as certainly manner calls elements market support RMR, by in which release, designed currently to what mean? For over are now, approach, acute the at a through as asked, Limited which SkinTE. surgical across scar well to for as market a truly market conferences, company access it this system, top have stages, where many of it always system And access support to
steps about long-term understand process early stress the reimbursement the provider addition, and of SkinTE a focus to The the or those run. product a of care an must surrounding full-scale achieve for we process basic the to variety those about to In of In SkinTE. year SkinTE and drive for defect those required types. provider, is pay success market will optimizing accessed we're release payer clinical be and of system NMR the testing and sales conventional tailoring understand market of to our release, have process, robust systems this FMR The settings, NMR national we user, with in specifically SkinTE. product. utilize further of directed will growth, code in cycle order accounts stages a a and represents approach market The our More RMR, regional effective in on and said order across with sales some importance concepts process penetration activation development and adoption. as cycle toward for RMR, the accounts our facility market the receipt networks, just product long the January,
for pay the this stages diagram, product. required SkinTE in can to that providers you Here SkinTE key see comprises process prior regularly cycle having sales
processes need use contact are These provide process, facilities. access the makes a and reimbursement established, four depending are access this a which First, types more And interest them significantly assessment see of and These for use options with agreement, value typically Kemp by paid to process. of include and SkinTE Matt Once different transition to as my include the Hague of Richard the clinical into may product access a on and SkinTE evaluation, a analysis sales a could there purchase different team evaluation optional educates with to on or desire products types which are providers size direct product. about of its system. time. one transitional and trial what more go that providers we in takes are agreement, optimal This outcomes the will trial evaluation detail facility. one committee, and/or colleagues gain
into for facility. purchase access this enter considered be stage, could a SkinTE within provider facility of clinical and/or allowing product the the of the setting or completion that agreement, and Following care sale This Polarity that is point facility into for sale the product more be It formal the the initiates for and product the access our sales revenue. drives system. adoption or deployed of team the to at this
our market that RMR. like the I'd we important limited learned initial of this to stage all have release from of now very our you and stage share Lastly, with
execution. on limited and with regional release the to To commercial, scale logistical product larger how intelligence market provided release use, system before the optimize While intelligence now date, providing on our is optimize strategies. reimbursement of to and how market it us our that, approaches, types has providers, all of patient-specific for impacted have learned and thus different is type we processes, and autologous requires and the developed practices while intents SkinTE by purposes, tailored teams same product,
eventually the across For receive execute while a the of time example, facilities, successful care been provider types, to and and required SkinTE practices do settings impact full of spectrum has processes the and purchase and clinical specific providers type agreement.
seen more small do, providers. We however, For well well product system with always healthcare landscape of a or systems. to have we systems trial remain payer and order maintain have only processes as across an setting utility economic specifically for for reimbursement private care reimbursement through in a clinic large approval future. SkinTE, typically prepared provide to therefore, studies payment effective, future clinical health to all Pertaining and, few designed example, settings, effective measurements have data, want SkinTE changes prospective than to office clinical public the successful in our valuable SkinTE reimbursement the and for the clinical into clinical as
in and market intelligence us plan sales of turn our force process release, of systems already strategic important. And Lastly, limited Mr. care into PolarityTE's some clinical the and toward while us our to Chief specific This providers, helping tailor call networks, more very Operating recent Officer. the over Thank to knew market of facilities the the impact a is market I'd specific regional clinical addition sales what settings of intermediate providers, you. to now, new SkinTE wounds, team, types to is we for our from greater Hague, with is all and Richard outcomes. trained clinical validate this this healthcare like to release providing and demand. being And practices, types
